Forecast

The analysts' average price target is +7,72€ (+118,70%). The median is +7,29€ (+106,52%).

Buy	10
Hold	3
Sell	7

News Go to news feed

MannKind achieves positive phase‑1b results for inhaled nintedanib in IPF

MannKind reports positive topline results from the randomized, double‑blind phase‑1b study INFLO‑1 of inhaled nintedanib as a dry powder in patients with idiopathic pulmonary fibrosis (IPF). The 27‑patient study showed no serious adverse events, no drug‑related gastrointestinal side effects, no bronchospasms and no discontinuations or dose reductions; cough was mostly mild and transient. Overall, IPF patients received about 450 inhalations; combined with phase‑1a, 48 people were treated, 18 of them with IPF. The global phase‑2 study INFLO‑2 to further evaluate nintedanib DPI is currently recruiting and is expected to enroll around 210 participants. » More on de.investing.com
Wells Fargo upgrades MannKind after pediatric Afrezza approval, calls commercial potential a “show‑me story”

Wells Fargo raised its price target on MannKind to $11 and kept an Overweight rating, citing FDA approval of Afrezza for patients aged 6 and older and supportive INHALE‑1 data. The approval expands Afrezza’s market to pediatric patients and caregivers. MannKind also highlighted potential near‑term upside from up to $35 million in development milestones, a 10% royalty on net sales and its role as sole manufacturer of Tyvaso DPI. » More on finance.yahoo.com
MannKind completes patient recruitment for INFLO‑1 and starts global phase‑2 for Nintedanib DPI

MannKind has completed randomization of patients in the phase‑1b trial INFLO‑1 and has enrolled the first patient in the global phase‑2 trial INFLO‑2 for Nintedanib DPI. INFLO‑1 evaluates safety, tolerability and pharmacokinetics; results are expected in Q3 2026. INFLO‑2 aims to recruit about 210 participants at roughly 85 sites in a randomized, double‑blind 1:1:1 design over 12 weeks (with a 24‑week open extension) for dose finding and safety assessment. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, MannKind Co. has already paid 7,52€ in dividends. The last payout was in September 2022.

Financials

In the last quarter, MannKind Co. had revenue of 95.83m€ and net profit of −16.68m€

(EUR)	Jun 2026	YoY
Revenue	+95.83m	47,60%
Gross profit	+69.95m	47,34%
Net profit	−16.68m	3.042,42%
EBITDA	+11.34m	37,10%

Fundamentals

Metric	Value
Market capitalization	+1.14b€
Number of shares	319.39m
52-week high/low	+5,59€ - +1,91€
Dividends	No
Beta	1,1
P/E ratio	−29,82
PEG ratio	+0,26
P/B ratio	−19,14
P/S ratio	+3,38

Company profile

MannKind Corporation, ein biopharmazeutisches Unternehmen, konzentriert sich auf die Entwicklung und Vermarktung von inhalativen therapeutischen Produkten für endokrine und seltene Lungenkrankheiten in den Vereinigten Staaten. Es bietet Afrezza an, ein inhalatives Insulin, das zur Verbesserung der Blutzuckerkontrolle bei Erwachsenen mit Diabetes eingesetzt wird. Außerdem vertreibt es Thyquidity an erwachsene und pädiatrische Endokrinologen und andere Gesundheitsdienstleister für die Behandlung von Hypothyreose. Das Unternehmen hat eine Lizenz- und Kooperationsvereinbarung mit United Therapeutics Corporation abgeschlossen. Darüber hinaus besteht eine Vereinbarung mit NRx Pharmaceuticals zur Entwicklung einer Trockenpulverformulierung von ZYESAMI (Aviptadil), einer synthetischen Form des menschlichen vasoaktiven intestinalen Peptids zum Schutz von Zellen vor Entzündungen. Die MannKind Corporation wurde 1991 gegründet und hat ihren Hauptsitz in Westlake Village, Kalifornien.